What's New
Front Page
Public Benefits When Notable Names Share Neurological Challenges, UCLA Professor Writes
In an opinion piece published last month in the Los Angeles Times, Keith Vossel, MD, of the…
Advancing Hope: AFTD Holds 2023 Holloway Summit Meeting on Biomarkers for FTD
The second annual AFTD Holloway Summit, focused on biomarkers for FTD, was held from November 30 to…
Dear HelpLine: Dealing With Genetic Uncertainty
Dear HelpLine, Each time I visit home for the holidays and see firsthand how FTD has affected…
AFTD and ADDF Extend Treat FTD Fund Program Through 2035
AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have committed to extending the Treat FTD Fund program…
The Lived Experience of FTD: Grief on the FTD Journey
The following article was written by members of AFTD’s Persons with FTD Advisory Council, who work to…
Passage Bio Announces Hopeful Initial Data from Phase 1/2 Clinical Trial
Passage Bio released promising preliminary results from its phase 1/2 clinical trial evaluating an experimental treatment for…
Tips & Advice: Navigating Apathy in FTD
A hallmark symptom of FTD, apathy can be particularly hard to deal with for persons diagnosed, care…
Advancing Hope: AFTD hosts FTD Social at the Society for Neuroscience Annual Meeting
The Society for Neuroscience (SfN), with nearly 35,000 members in 95 countries, is the world’s largest professional…
Editor Shares How Basketball Helps Him Bond with Friend Who Has PPA
Retired managing editor Lonny Cain of The Times (Ottawa, Ill.) shared in a recent article how basketball…
“We’re Just Regular People with an Illness,” Dementia Advocate with FTD Writes in Essay
In an essay published by Inside Ageing, Bobby Redman, a retired behavioral psychologist living with FTD, discusses…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)